TY - JOUR
T1 - The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction
AU - Duffy, Danielle
AU - Holmes, Dajuanicia N.
AU - Roe, Matthew T.
AU - Peterson, Eric D.
N1 - Funding Information:
Dr Duffy has received research funding from Abbott Laboratories, Forest Laboratories, and Roche/Genetech. Ms Holmes has no disclosures to report. Dr Roe has received research funding from the American College of Cardiology, the American Heart Association, Bristol-Myers Squibb, Eli Lilly, Merck-Schering-Plough, and Novartis. He has received consulting fees or honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, KAI Pharmaceuticals, Orexigen, Novartis, and Sanofi-Aventis. Dr Peterson has received research funding from Bristol-Myers Squibb/Sanofi-Aventis and Merck.
PY - 2012/4
Y1 - 2012/4
N2 - Background: Low serum high-density lipoprotein cholesterol (HDL-C) level is a potent risk factor for developing atherosclerosis, yet it is uncertain if HDL-C level at the time of non-ST-segment elevation myocardial infarction (NSTEMI) has downstream prognostic importance. Methods: We evaluated 24,805 patients with NSTEMI aged ≥ 65 years enrolled at 434 Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) participating hospitals between February 15, 2003, and December 30, 2006, who had clinical data linked to Medicare files through December 31, 2008. Unadjusted and adjusted hazard ratios (HRs) were calculated to determine the association between HDL-C level at initial hospitalization and all-cause mortality, as well as a combined outcome of all-cause mortality or recurrent myocardial infarction (MI). Results: Overall, 50% of patients had low HDL-C (≤40 mg/dL) and 18% had very low HDL-C (≤30 mg/dL). The rate of all-cause mortality was 39.5% during a median follow-up of 2.9 years; death or recurrent MI occurred in 43% in this older population with NSTEMI. Compared with patients who had normal HDL-C, those with very low HDL-C had a modest but significantly higher long-term mortality risk (adjusted HR 1.12, 95% CI 1.06-1.19, P =.0001). The adjusted HR for mortality or recurrent MI was the same. When modeled as a continuous variable, every 5-mg/dL decrement in HDL-C below 40 mg/dL was associated with a 5% increased risk of long-term mortality, as well as the combined end point. Conclusions: Older patients with NSTEMI with low levels of HDL-C are at increased risk for downstream mortality or recurrent MI. Future studies are needed to evaluate strategies to reduce this residual risk.
AB - Background: Low serum high-density lipoprotein cholesterol (HDL-C) level is a potent risk factor for developing atherosclerosis, yet it is uncertain if HDL-C level at the time of non-ST-segment elevation myocardial infarction (NSTEMI) has downstream prognostic importance. Methods: We evaluated 24,805 patients with NSTEMI aged ≥ 65 years enrolled at 434 Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) participating hospitals between February 15, 2003, and December 30, 2006, who had clinical data linked to Medicare files through December 31, 2008. Unadjusted and adjusted hazard ratios (HRs) were calculated to determine the association between HDL-C level at initial hospitalization and all-cause mortality, as well as a combined outcome of all-cause mortality or recurrent myocardial infarction (MI). Results: Overall, 50% of patients had low HDL-C (≤40 mg/dL) and 18% had very low HDL-C (≤30 mg/dL). The rate of all-cause mortality was 39.5% during a median follow-up of 2.9 years; death or recurrent MI occurred in 43% in this older population with NSTEMI. Compared with patients who had normal HDL-C, those with very low HDL-C had a modest but significantly higher long-term mortality risk (adjusted HR 1.12, 95% CI 1.06-1.19, P =.0001). The adjusted HR for mortality or recurrent MI was the same. When modeled as a continuous variable, every 5-mg/dL decrement in HDL-C below 40 mg/dL was associated with a 5% increased risk of long-term mortality, as well as the combined end point. Conclusions: Older patients with NSTEMI with low levels of HDL-C are at increased risk for downstream mortality or recurrent MI. Future studies are needed to evaluate strategies to reduce this residual risk.
UR - http://www.scopus.com/inward/record.url?scp=84860137956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860137956&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2012.01.029
DO - 10.1016/j.ahj.2012.01.029
M3 - Article
C2 - 22520538
AN - SCOPUS:84860137956
SN - 0002-8703
VL - 163
SP - 705
EP - 713
JO - American Heart Journal
JF - American Heart Journal
IS - 4
ER -